THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...

The FDA has expanded the approval of Repatha to reduce the risk of major adverse cardiovascular events in adults at increased risk for these events.

Almost all (95%) Medicare drug plans cover Repatha. This includes standalone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Repatha is a brand ...

Amgen’s cholesterol drug Repatha proved effective at lowering the risk of heart attacks, strokes and death in patients with heart disease in a recent clinical trial, reports Reuters. When reporting ...

Amgen (AMGN) announced that the U.S. FDA has broadened the approved use of Repatha to include adults at increased risk for major adverse ...

It’s not known whether Repatha (evolocumab) is safe to receive while pregnant or breastfeeding. Certain factors may determine whether you can receive the drug during this time. If you may be or can ...

Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...